{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-029868","form_type":"8-K","ticker":"ZVSA","cik":"0001859007","company_name":"ZyVersa Therapeutics, Inc.","filed_at":"2024-08-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.980277+00:00","generated_at":"2026-05-31T14:01:41.213449+00:00","sec_items":["1.01","3.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"ZyVersa raises ~$830k via warrant inducement at $3.46; issues 200% new warrants","bullets":["Holder exercises existing Series A/B warrants at reduced price $3.46 (from $12.50), gross proceeds ~$830k.","New Series A-1 warrants for 392k shares (5-yr term) and Series B-1 for 86.6k shares (18-mo term), all at $3.46.","New warrant shares subject to stockholder approval; meeting to be held within 90 days of closing.","Engaged A.G.P./Alliance Global Partners as financial advisor for $50k cash fee.","Company to file resale registration statement for new warrant shares by September 2, 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-029868","json":"https://secwatch.observer/filing/0001493152-24-029868.json","markdown":"https://secwatch.observer/filing/0001493152-24-029868.md","text":"https://secwatch.observer/filing/0001493152-24-029868.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1859007/000149315224029868/0001493152-24-029868-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1859007/000149315224029868/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T14:01:41.213449+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}